36 results about "Adalimumab" patented technology

Methods for treating chronic wounds in a human are described by topically administering a dermatological composition comprising a TNF antagonist, a TACE inhibitor, a neutrophil antagonist, or a combination of a TNF antagonist and/or TACE inhibitor and a neutrophil antagonist. The TNF antagonist administered includes alefacept, efalizumab, etanercept, adalimumab, and onercept, while the neutrophil antagonist administered includes dapsone, colchicine, its analogs and prodrugs. The combination of TNF-antagonist and neutrophil antagonist administered includes sulfapyridine, sulfasalazine, mesalamine, and derivatives and prodrugs thereof. The topical compositions can be formulated to include the one or more of the antagonists in dissolved, semi-dissolved, and micro-particulate states.

The present invention provides assay methods for the determination of one or more anti-drug antibody (ADA) isotypes in a sample. As a non-limiting example, the assays of the present invention are particularly useful for determining different ADA isotypes in samples from ADA-positive patients receiving an anti-TNFα drug such as REMICADE™ (infliximab) or HUMIRA™ (adalimumab). The present invention also provides methods for optimizing therapy and/or reducing toxicity in subjects receiving TNFα inhibitors for the treatment of TNFα-mediated disease or disorders.

Disclosed is a pharmaceutical composition comprising adalimumab and a structural protective agent, wherein the structural protective agent is selected from sucrose or trehalose, and the pharmaceutical composition has a high stability.

A liquid pharmaceutical composition having an anti-TNFα antibody, a buffer, a stabilizer, and a surfactant.

The invention discloses a combined medium for expressing adalimumab. The combined medium is composed of a basic medium and a fed medium, wherein the basic medium is composed of CD FortiCHO and M20A ina ratio of 1: 0.5-1.5; the fed medium consists of F001S and F001B in a ratio of 5-15: 1; and the above mediums are both commercial mediums. Individual usage of any of the mediums cannot produce high-yield stable adalimumab; but the combined medium of the basic medium and the fed medium can significantly increase the expression quantity of adalimumab and improve cell density and cell viability, stably overcomes the problem of accumulation of a large amount of lactic acid and low yield of target proteins in conventional adalimumab cell culture processes, and is beneficial for further improvement of the output and quality of adalimumab.

The invention relates to a primer pair and a kit for detecting related gene polymorphism of adalimumab medication, and belongs to the technical field of in-vitro nucleic acid detection. The primer pair comprises amplification primers aiming at TNFrs1800629, KLRC1rs7301582, FCGR2Ars1801274, PTPRCrs10919563, HLA-Ers1264457, TRAF1rs3761847 and KLRD1rs2302489 allelic genes and GAPDH reference genes respectively. The kit comprises a primer solution containing the amplification primers. The kit provided by the invention is high in sensitivity which can reach one ten- thousandth, and the lowest detection limit is only 1-2copies, so that the kit is particularly suitable for detecting low-content mutation samples; and compared with a sequencing method, a detection result can be observed in real time, a product does not need gel electrophoresis detection, tube closing operation is completely carried out, and the risk of PCR product pollution is effectively reduced; and in addition, the kit has the advantages of being high in detection speed and suitable for high-throughput sample detection.

The present invention provides antigen binding proteins which bind specifically to TNF-alpha. For example novel variants of anti-TNF antibodies such as adalimumab which show increased binding to the FcRn receptor or increased half life compared to adalimumab. Also provided are compositions comprising the antigen binding proteins and uses of such compositions in treatment of disorders and disease.

The invention discloses a recombinant vector for enhancing the ability of displaying Fab fragment antigen binding on the yeast cell surface by using endoplasmic reticulum retrieval signal sequences, and belongs to the technical field of antibody engineering. A GAL1-GAL10 bidirectional promoter vector is used for expressing two structures domains at the same time, namely VH-CH1 and VL-CL, of Adalimumab or Infliximab, and the amino terminal endoplasmic reticulum retrieval signal sequences are located in an endoplasmic reticulum and assembled into natural Fab form fragments to be displayed on thecell surface through an Aga1-Aga2 yeast cell display system. Meanwhile, by fusing the saccharomyces cerevisiae retrieval signal sequences into the carboxyl terminal of the Fab fragment VL-CL structure domain, the ability of the yeast cell surface to display Fab fragment bonded antigens is greatly improved, displaying of functional Fab fragments is promoted, the vector is more suitable for displaying the Fab fragments on the yeast cell surface, and an optimization strategy is provided for Fab modification in antibody engineering.

A pharmaceutical composition comprises a buffer-less aqueous formulation of adalimumab, a salt, a polyol, and a polysorbate. The formulation is suitable for injection.

The invention discloses a method for purifying adalimumab by the aid of cation exchange chromatography. The method has the advantages that pollutants in mixtures with antibodies and the pollutants are removed by urea and betaine surfactants which are added in CEX (cation exchange) multi-step elution procedures, polymers are separated from the antibodies, then hydrophobic interaction chromatography is carried out, and accordingly good pollutant separation effects can be realized; samples are easy to regulate in chromatography procedures, drastic change of pH (potential of hydrogen) values can be prevented, and the contents of polymers in ultimately purified products can be obviously lowered.

The invention provides an affinity chromatography method for removing antibody aggregates and degradation fragments and improving the yield and purity of antibody single bodies. The purity of the antibody single body is improved by optimizing parameter conditions such as pH value, conductivity and buffer solution type in the affinity chromatography process of the recombinant adalimumab, and then the yield of the antibody singer body is improved by adding urea or a PEG additive into an elution buffer solution. In a preferred embodiment, the yield of the recombinant adalimumab single body can reach 90%, and the purity of the single body in the product exceeds 95%.

The invention relates to a DNA transmethylase Dnmt3b gene deficient type CHO (Chinese hamster ovary) cell line, a preparation method and application thereof and a recombinant protein expression system, and belongs to the technical field of genetic engineering. CHO cell Dnmt3b gene is knocked off by CRISPR/Cas9 gene editing technique so as to obtain the Dnmt3b gene deficient type CHO cell line is attained; the Dnmt3b gene deficient type CHO cell line can evidently increase the expression level and expression stability of a target gene in CHO cells, and the problem can be solved that existing CHO cell expression systems have low expression level and expression instability; upon expression of recombinant Adalimumab with the cell line herein, it is discovered that the expression level of the recombinant Adalimumab is increased evidently. Therefore, the cell line of the invention is widely applicable to the expression of target proteins.

A method of treating a medical condition with a combination of substances, wherein one of the substances is adalimumab, in combination with a computer program configured for: providing a patient with sets of questions adapted to the combination, to adalimumab, and to the non-adalimumab substances, wherein at least one of the sets of questions is related to perceived and/or measured therapeutic effects; subjecting the answers to the sets of questions to functions, thereby generating patient specific feedback; and adjusting a dosage of at least one substance based at least in part on the patient-specific feedback.

The invention provides an ADA instant detection test strip and kit for adalimumab drug, and belongs to the technical field of clinical rapid (instant) detection and anti-drug antibody bioanalysis, the ADA instant detection test strip comprises a sample gold-labeled integrated pad, a nitrocellulose membrane and absorbent cotton; a sample adding hole and a gold marking line are arranged on the sample-gold marking integrated pad; an adalimumab colloidal gold conjugate and a chicken IgY colloidal gold conjugate are sprayed on the gold marking line; a detection line and a quality control line are arranged on the nitrocellulose membrane, a mouse anti-human IgG monoclonal antibody is sprayed on the detection line, and a goat anti-chicken IgY polyclonal antibody is sprayed on the quality control line. By adopting the ADA instant detection test strip provided by the invention, a detection result can be obtained within 15 minutes, and expensive instruments are not needed.